Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors

Abstract excerpt

Prevention of bleeding, especially into joints, with prophylactic factor infusions is the most effective treatment for severe haemophilia patients. Approximately 15-30% of patients with factor VIII deficiency and 3-5% of patients with factor IX deficiency develop neutralizing antibodies (inhibitors) to factor precluding their use. Such patients often have significant bleeding complications including life- and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Blood Coagulation and Thrombosis Mechanisms
• Share to Hemophilia Treatment and Research